Product Description
for the Treatment of Moderate to Severe COVID-19 Patients. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04900337)
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: N/A
Route of Administration: Sublingual,Inhalant
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Amorphical
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Israel
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: COVID-19
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
AMCS-COVID-001 | P2 |
Completed |
COVID-19 |
2023-06-30 |
25% |